Prevalence of drug resistance mutations in HAART patients infected with HIV‐1 CRF06_cpx in Estonia
- 20 August 2015
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 88 (3) , 448-454
Abstract
HIV‐1 drug resistance mutations (DRMs) and substitutions were assessed after the failure of the first line non‐nucleoside reverse transcriptase inhibitors (NNRTIs) + 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) treatment regimens (efavirenz [EFV] + lamivudine[3TC] + zidovudine [ZDV] vs. EFV + 3TC + ddI) among the HIV‐1 CRF06_cpx infected subjects in Estonia. HIV‐1 genomic RNA was sequenced; DRMs and amino acid substitutions were compared in 44 treatment naïve and 45 first‐line NNRTI + 2 NRTI treatment failed patients consisting of EFV + 3TC + ZDV (n = 17) and EFV + 3TC + didanosine[ddI] (n = 21) therapy failed sub‐populations. At least one DRM was found in 78% of treatment experienced patients. The most common NRTI mutations were M184V (80%), L74V (31%), L74I (17%), K219E (9%), and M184I (9%), NNRTI mutations were K103N (83%), P225H (14%), L100I (11%), and Y188L (11%), reflecting generally the similar pattern of DRMs to that seen in treatment failed subtype B viruses. Sub‐population analysis revealed that EFV + 3TC + ddI failed patients had more DRMs compared to EFV + 3TC + ZDV failed patients, especially the ddI DRM L74IV and several additional NNRTI DRMs. Additionally, CRF06_cpx specific mutation E179V and substitutions R32K, K122E, and V200AE were also detected in treatment experienced population. After the failure of the first‐line EFV + 3TC + ddI therapy HIV‐1 CRF06_cpx viruses develop additional NRTI and NNRTI mutations compared to EFV + 3TC + ZDV regimen. Therefore the usage of EFV + 3TC + ddI in this subtype decreases the options for next regimens containing abacavir, and NNRTI class agents. J. Med. Virol. 88:???–???, 2016.Keywords
Funding Information
- European Regional Development Fund; Estonian Science Foundation (8004, 8415, 8856)
- Basic Financing and the Target Financing of Estonian Ministry of Education and Research (SF0180004s12, SF0182726s06)
This publication has 28 references indexed in Scilit:
- Are subtype differences important in HIV drug resistance?Current Opinion in Virology, 2012
- Estonia at the Threshold of the Fourth Decade of the AIDS Era in EuropeAIDS Research and Human Retroviruses, 2011
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony MethodsMolecular Biology and Evolution, 2011
- Long‐term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral‐naive patients: a 9‐year cohort study in SenegalTropical Medicine & International Health, 2010
- Emerging transmitted drug resistance in treatment-naïve human immunodeficiency virus-1 CRF06_cpx-infected patients in EstoniaScandinavian Journal of Infectious Diseases, 2010
- HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutationsAntiviral Therapy, 2010
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South AfricaClinical Infectious Diseases, 2008
- Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI StudyAIDS Research and Human Retroviruses, 2007
- Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global CollaborationPLOS Medicine, 2005
- First Report of CRF03_AB Recombinant HIV Type 1 in Injecting Drug Users in UkraineAIDS Research and Human Retroviruses, 2002